Biogen (BIIB) Income from Continuing Operations (2009 - 2026)

Biogen has reported Income from Continuing Operations for 18 years, with the latest figure at $97.5 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 84.64% year-over-year to $97.5 million in Q2 2026; TTM through Jun 2026 was $834.6 million, a 45.47% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 20.79% from the prior year.
• Income from Continuing Operations was $97.5 million for Q2 2026 at Biogen, down from $319.5 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $1.1 billion in Q3 2022, with the low at -$68.3 million in Q3 2023.
• Average Income from Continuing Operations over 5 years is $414.6 million, with a median of $388.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations soared 1538.48% in 2022, then slumped 118.34% in 2025.
• Over 5 years, Income from Continuing Operations stood at $549.5 million in 2022, then slumped by 54.7% to $248.9 million in 2023, then climbed by 7.15% to $266.7 million in 2024, then plunged by 118.34% to -$48.9 million in 2025, then jumped by 299.39% to $97.5 million in 2026.
• The last three Income from Continuing Operations figures came in at $97.5 million (Q2 2026), $319.5 million (Q1 2026), and -$48.9 million (Q4 2025), per Business Quant data.